Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components.

The forkhead transcription factor forkhead box protein O1 (FoxO1), a downstream target of phosphatidylinositol 3-kinase/Akt signaling, has been reported to suppress skeletal myocyte differentiation, but the mechanism by which FoxO1 regulates myogenesis is not fully understood. We have previously demonstrated that a nutrient-sensing mammalian target of rapamycin (mTOR) pathway controls the autocrine production of IGF-II and the subsequent phosphatidylinositol 3-kinase/Akt signaling downstream of IGF-II in myogenesis. Here we report a regulatory loop connecting FoxO1 to the mTOR pathway. Inducible activation of a FoxO1 active mutant in the C2C12 mouse myoblasts blocks myogenic differentiation at an early stage and meanwhile leads to proteasome-dependent degradation of a specific subset of components in the mTOR signaling network, including mTOR, raptor, tuberous sclerosis complex 2, and S6 protein kinase 1. This function of FoxO1 requires new protein synthesis, consistent with the idea that a transcriptional target of FoxO1 may be responsible for the degradation of mTOR. We further show that active FoxO1 inhibits IGF-II expression at the transcriptional activation level, through the modulation of mTOR protein levels. Moreover, the addition of exogenous IGF-II fully rescues myocyte differentiation from FoxO inhibition. Taken together, we propose that the mTOR-IGF-II pathway is a major mediator of FoxO's inhibitory function in skeletal myogenesis.

[1]  R. DePinho,et al.  A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. , 2007, The Journal of clinical investigation.

[2]  M. Febbraio,et al.  FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle* , 2007, Journal of Biological Chemistry.

[3]  N. Mochizuki,et al.  Interaction of FoxO1 and TSC2 Induces Insulin Resistance through Activation of the Mammalian Target of Rapamycin/p70 S6K Pathway* , 2006, Journal of Biological Chemistry.

[4]  Daniel J. Hoeppner,et al.  Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.

[5]  K. Ikeda,et al.  A novel ubiquitin‐binding protein ZNF216 functioning in muscle atrophy , 2006, The EMBO journal.

[6]  In-Hyun Park,et al.  Mammalian Target of Rapamycin (mTOR) Signaling Is Required for a Late-stage Fusion Process during Skeletal Myotube Maturation*[boxs] , 2005, Journal of Biological Chemistry.

[7]  T. Rando,et al.  The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. , 2005, Seminars in cell & developmental biology.

[8]  T. Unterman,et al.  FoxO proteins in insulin action and metabolism , 2005, Trends in Endocrinology & Metabolism.

[9]  Joseph Avruch,et al.  Rheb Binds and Regulates the mTOR Kinase , 2005, Current Biology.

[10]  K. Esser,et al.  FoxO1 Stimulates Fatty Acid Uptake and Oxidation in Muscle Cells through CD36-dependent and -independent Mechanisms* , 2005, Journal of Biological Chemistry.

[11]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[12]  Di Chen,et al.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.

[13]  D. Accili,et al.  FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.

[14]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[15]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[16]  Michael Majeski,et al.  Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. , 2004, The Biochemical journal.

[17]  In-Hyun Park,et al.  IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients , 2003, The Journal of cell biology.

[18]  Hitomi Matsuzaki,et al.  Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Accili,et al.  Regulation of insulin-like growth factor–dependent myoblast differentiation by Foxo forkhead transcription factors , 2003, The Journal of cell biology.

[20]  J. Lawrence,et al.  Two Motifs in the Translational Repressor PHAS-I Required for Efficient Phosphorylation by Mammalian Target of Rapamycin and for Recognition by Raptor* , 2003, Journal of Biological Chemistry.

[21]  J. Blenis,et al.  TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function , 2003, Current Biology.

[22]  J. Avruch,et al.  The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif* , 2003, The Journal of Biological Chemistry.

[23]  Eric C. Griffith,et al.  The Many Forks in FOXO's Road , 2003, Science's STKE.

[24]  G. Grosveld,et al.  FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts , 2003, The EMBO journal.

[25]  O. Hino,et al.  Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling , 2002, Nature Cell Biology.

[26]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[27]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[28]  P. Houghton,et al.  Myogenic Differentiation Is Dependent on Both the Kinase Function and the N-terminal Sequence of Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.

[29]  F. Barr,et al.  Molecular Pathogenesis of Rhabdomyosarcoma , 2002, Cancer biology & therapy.

[30]  C. R. Kaffer,et al.  Regulatory Mechanisms at the MouseIgf2/H19 Locus , 2001, Molecular and Cellular Biology.

[31]  Jie Chen,et al.  The Mammalian Target of Rapamycin Regulates C2C12 Myogenesis via a Kinase-independent Mechanism* , 2001, The Journal of Biological Chemistry.

[32]  Antonio Musarò,et al.  Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.

[33]  M. Benito,et al.  Insulin produces myogenesis in C2C12 myoblasts by induction of NF‐κB and downregulation of AP‐1 activities , 2001, Journal of cellular physiology.

[34]  E. Olson,et al.  MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. , 1999, Current opinion in cell biology.

[35]  A. Musarò,et al.  Maturation of the Myogenic Program Is Induced by Postmitotic Expression of Insulin-Like Growth Factor I , 1999, Molecular and Cellular Biology.

[36]  P. Vogt,et al.  Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Cohen,et al.  Stress-activated Protein Kinase-2/p38 and a Rapamycin-sensitive Pathway Are Required for C2C12 Myogenesis* , 1999, The Journal of Biological Chemistry.

[38]  A. Musarò,et al.  Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Vogt,et al.  An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Palacín,et al.  Phosphatidylinositol 3-Kinase Inhibitors Block Differentiation of Skeletal Muscle Cells* , 1996, The Journal of Biological Chemistry.

[41]  Harold Weintraub,et al.  The MyoD family and myogenesis: Redundancy, networks, and thresholds , 1993, Cell.

[42]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[43]  J R Florini,et al.  "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. , 1991, The Journal of biological chemistry.

[44]  P. Rotwein,et al.  Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. , 1989, The Journal of biological chemistry.

[45]  P. Rotwein,et al.  Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Palacín,et al.  Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. , 1998, Molecular endocrinology.

[47]  J. Florini,et al.  Hormones, growth factors, and myogenic differentiation. , 1991, Annual review of physiology.